Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes

Implications for insulin resistance, inflammation, and atherosclerosis

S. J. Yang, S. Y. Hwang, H. Y. Choi, Hye-Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei-Hyun Baik, D. S. Choi, Kyung Mook Choi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Context and Objective: The dysregulation of hepatokinesmaybe associated with the pathogenesis of insulin resistance and type 2 diabetes. A recent study has suggested that selenoprotein P (SeP), a novel hepatokine, may play a role in the regulation of glucose metabolism and insulin sensitivity. We examined the relationship between circulating SeP levels and clinical parameters associated with insulin resistance in humans. Participants and Methods: We compared serum SeP concentrations in 100 subjects with diverse glucose tolerance statuses. Furthermore, we evaluated the relationship between SeP and cardiometabolic risk factors including insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness. Results: Serum SeP concentrations were significantly higher in patients with type 2 diabetes or prediabetes than those with normal glucose tolerance (all P < 0.01) and decreased in a stepwise manner [1032.4 (495.9-2149.4) vs. 867.3 (516.3-1582.7) vs. 362.0 (252.5-694.5), P = 0.004]. In addition, overweight and obese subjects had significantly increased SeP levels compared with lean subjects (P = 0.002). Spearman's partial correlation analysis adjusted for age and gender showed a significant relationship between SeP and cardiometabolic factors including body mass index, waist circumference, systolic blood pressure, triglycerides, glucose, hemoglobin A1c, aspartate aminotransferase, and insulin resistance. Furthermore, in multiple regression analyses, SeP showed an independent association with carotid intima-media thickness as well as high-sensitivity C-reactive protein, even after adjustment for other confounding factors. Conclusions: Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulationandwere related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis.

Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number8
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Selenoprotein P
Prediabetic State
Medical problems
Type 2 Diabetes Mellitus
Insulin Resistance
Atherosclerosis
Insulin
Inflammation
Serum
Glucose
Carotid Intima-Media Thickness
Metabolism
C-Reactive Protein
Blood Pressure
Blood pressure
Waist Circumference
Aspartate Aminotransferases
Hemoglobins
Triglycerides
Body Mass Index

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{e1e18bea02ac437e98ae48547705243e,
title = "Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis",
abstract = "Context and Objective: The dysregulation of hepatokinesmaybe associated with the pathogenesis of insulin resistance and type 2 diabetes. A recent study has suggested that selenoprotein P (SeP), a novel hepatokine, may play a role in the regulation of glucose metabolism and insulin sensitivity. We examined the relationship between circulating SeP levels and clinical parameters associated with insulin resistance in humans. Participants and Methods: We compared serum SeP concentrations in 100 subjects with diverse glucose tolerance statuses. Furthermore, we evaluated the relationship between SeP and cardiometabolic risk factors including insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness. Results: Serum SeP concentrations were significantly higher in patients with type 2 diabetes or prediabetes than those with normal glucose tolerance (all P < 0.01) and decreased in a stepwise manner [1032.4 (495.9-2149.4) vs. 867.3 (516.3-1582.7) vs. 362.0 (252.5-694.5), P = 0.004]. In addition, overweight and obese subjects had significantly increased SeP levels compared with lean subjects (P = 0.002). Spearman's partial correlation analysis adjusted for age and gender showed a significant relationship between SeP and cardiometabolic factors including body mass index, waist circumference, systolic blood pressure, triglycerides, glucose, hemoglobin A1c, aspartate aminotransferase, and insulin resistance. Furthermore, in multiple regression analyses, SeP showed an independent association with carotid intima-media thickness as well as high-sensitivity C-reactive protein, even after adjustment for other confounding factors. Conclusions: Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulationandwere related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis.",
author = "Yang, {S. J.} and Hwang, {S. Y.} and Choi, {H. Y.} and Hye-Jin Yoo and Seo, {Ji A} and Kim, {Sin Gon} and Kim, {Nan Hee} and Sei-Hyun Baik and Choi, {D. S.} and Choi, {Kyung Mook}",
year = "2011",
month = "8",
day = "1",
doi = "10.1210/jc.2011-0620",
language = "English",
volume = "96",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes

T2 - Implications for insulin resistance, inflammation, and atherosclerosis

AU - Yang, S. J.

AU - Hwang, S. Y.

AU - Choi, H. Y.

AU - Yoo, Hye-Jin

AU - Seo, Ji A

AU - Kim, Sin Gon

AU - Kim, Nan Hee

AU - Baik, Sei-Hyun

AU - Choi, D. S.

AU - Choi, Kyung Mook

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Context and Objective: The dysregulation of hepatokinesmaybe associated with the pathogenesis of insulin resistance and type 2 diabetes. A recent study has suggested that selenoprotein P (SeP), a novel hepatokine, may play a role in the regulation of glucose metabolism and insulin sensitivity. We examined the relationship between circulating SeP levels and clinical parameters associated with insulin resistance in humans. Participants and Methods: We compared serum SeP concentrations in 100 subjects with diverse glucose tolerance statuses. Furthermore, we evaluated the relationship between SeP and cardiometabolic risk factors including insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness. Results: Serum SeP concentrations were significantly higher in patients with type 2 diabetes or prediabetes than those with normal glucose tolerance (all P < 0.01) and decreased in a stepwise manner [1032.4 (495.9-2149.4) vs. 867.3 (516.3-1582.7) vs. 362.0 (252.5-694.5), P = 0.004]. In addition, overweight and obese subjects had significantly increased SeP levels compared with lean subjects (P = 0.002). Spearman's partial correlation analysis adjusted for age and gender showed a significant relationship between SeP and cardiometabolic factors including body mass index, waist circumference, systolic blood pressure, triglycerides, glucose, hemoglobin A1c, aspartate aminotransferase, and insulin resistance. Furthermore, in multiple regression analyses, SeP showed an independent association with carotid intima-media thickness as well as high-sensitivity C-reactive protein, even after adjustment for other confounding factors. Conclusions: Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulationandwere related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis.

AB - Context and Objective: The dysregulation of hepatokinesmaybe associated with the pathogenesis of insulin resistance and type 2 diabetes. A recent study has suggested that selenoprotein P (SeP), a novel hepatokine, may play a role in the regulation of glucose metabolism and insulin sensitivity. We examined the relationship between circulating SeP levels and clinical parameters associated with insulin resistance in humans. Participants and Methods: We compared serum SeP concentrations in 100 subjects with diverse glucose tolerance statuses. Furthermore, we evaluated the relationship between SeP and cardiometabolic risk factors including insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness. Results: Serum SeP concentrations were significantly higher in patients with type 2 diabetes or prediabetes than those with normal glucose tolerance (all P < 0.01) and decreased in a stepwise manner [1032.4 (495.9-2149.4) vs. 867.3 (516.3-1582.7) vs. 362.0 (252.5-694.5), P = 0.004]. In addition, overweight and obese subjects had significantly increased SeP levels compared with lean subjects (P = 0.002). Spearman's partial correlation analysis adjusted for age and gender showed a significant relationship between SeP and cardiometabolic factors including body mass index, waist circumference, systolic blood pressure, triglycerides, glucose, hemoglobin A1c, aspartate aminotransferase, and insulin resistance. Furthermore, in multiple regression analyses, SeP showed an independent association with carotid intima-media thickness as well as high-sensitivity C-reactive protein, even after adjustment for other confounding factors. Conclusions: Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulationandwere related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=79961235988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961235988&partnerID=8YFLogxK

U2 - 10.1210/jc.2011-0620

DO - 10.1210/jc.2011-0620

M3 - Article

VL - 96

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -